NEUROCRINE BIOSCIENCES INC Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses (Deprecated 2013-01-31)
NEUROCRINE BIOSCIENCES INC (NBIX) had Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses (Deprecated 2013-01-31) of $66.00 thousand as of 2013-03-31, per its 10-Q filed 2013-05-02.
Discontinued › Notes › Investments
us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses2 · last filed 2013-05-02
- 2013-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses (Deprecated 2013-01-31) $66.00K.
- 2012-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses (Deprecated 2013-01-31) $35.00K.
- 2012-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses (Deprecated 2013-01-31) $28.00K.
- 2012-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses (Deprecated 2013-01-31) $147.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses (Deprecated 2013-01-31) |
|---|---|
| 2013-03-31 | $66.00K 10-Q · filed 2013-05-02 |
| 2012-12-31 | $35.00K 10-Q · filed 2013-05-02 |
| 2012-09-30 | $28.00K 10-Q · filed 2012-10-31 |
| 2012-06-30 | $147.00K 10-Q · filed 2012-07-31 |
| 2011-12-31 | $95.00K 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |